Who are Apacil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Azovan Blue, Emcyt, Apacil, REZIPAS, Octadecanoic Acid, Asacol (mesalamine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aminosalicylic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Apacil — Competitive Intelligence Brief

Apacil (AMINOSALICYLIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aminosalicylic acid. Area: Immunology.

marketed aminosalicylic acid Tyrosine-protein phosphatase non-receptor type 1 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Apacil (AMINOSALICYLIC ACID) — Consolidated Midland.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apacil TARGET	AMINOSALICYLIC ACID	Consolidated Midland	marketed	aminosalicylic acid	Tyrosine-protein phosphatase non-receptor type 1	1950-01-01
Azovan Blue	EVANS BLUE	Pfizer	marketed		Ectonucleotide pyrophosphatase/phosphodiesterase family member 2, Tyrosine-protein phosphatase non-receptor type 1, Luciferin 4-monooxygenase	1982-01-01
Emcyt	ESTRAMUSTINE PHOSPHATE	Pfizer	marketed	estramustine phosphate	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2, Protein-tyrosine phosphatase 1C, Tyrosine-protein phosphatase non-receptor type 1	1981-01-01
Apacil	AMINOSALICYLATE SODIUM	Consolidated Midland	marketed	aminosalicylic acid	Tyrosine-protein phosphatase non-receptor type 1	1950-01-01
REZIPAS	AMINOSALICYLIC ACID RESIN COMPLEX	BRISTOL MYERS SQUIBB	marketed		Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
Octadecanoic Acid	stearic acid		marketed	stearic acid	Fatty acid-binding protein, adipocyte, Peroxisome proliferator-activated receptor delta, Tyrosine-protein phosphatase non-receptor type 1
Asacol (mesalamine)	Asacol (mesalamine)	University of Washington	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition; free radical scavenging

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (aminosalicylic acid class)

Consolidated Midland · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apacil — Competitive Intelligence Brief. https://druglandscape.com/ci/aminosalicylic-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab